CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,682 enrolled
Drug / intervention
Ezetimibedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01381679
NCT01381679N/ACompleted
CompareCT.gov

Austrian Cholesterol Screening And Treatment II (ACT II)

Organon and Co·observational·Posted Jun 27, 2011·Updated Feb 9, 2022

In Brief

An observational study evaluating Ezetimibe for Hypercholesterolemia. Completed, enrolled 1,682 participants.

Detailed Summary

This non-interventional longitudinal study is a follow-up of the Austrian Cholesterol Screening and Treatment project (ACT I), which assessed the cholesterol status, including achievement of the target levels applicable at that time (LDL levels \<100 mg/dL), in participants with coronary heart disease (CHD) already being treated with a statin. In this study, participants without adequate LDL-cholesterol reduction with a statin underwent extension of therapy with ezetimibe with the goal of achieving target levels.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHypercholesterolemia
Countries--
Collaborators--

Timeline

N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 27, 2011
Enrollment StartMay 1, 2009
Primary CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 15.0 years ago

Interventions

Ezetimibedrug

Ezetimibe was not mandatory and was prescribed as per routine prescription by physician.